JP2019517596A5 - - Google Patents

Download PDF

Info

Publication number
JP2019517596A5
JP2019517596A5 JP2019517187A JP2019517187A JP2019517596A5 JP 2019517596 A5 JP2019517596 A5 JP 2019517596A5 JP 2019517187 A JP2019517187 A JP 2019517187A JP 2019517187 A JP2019517187 A JP 2019517187A JP 2019517596 A5 JP2019517596 A5 JP 2019517596A5
Authority
JP
Japan
Prior art keywords
dicyano
thio
phenylacetamide
amino
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019517187A
Other languages
English (en)
Japanese (ja)
Other versions
JP7051829B2 (ja
JP2019517596A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/053511 external-priority patent/WO2017216727A1/en
Publication of JP2019517596A publication Critical patent/JP2019517596A/ja
Publication of JP2019517596A5 publication Critical patent/JP2019517596A5/ja
Application granted granted Critical
Publication of JP7051829B2 publication Critical patent/JP7051829B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019517187A 2016-06-13 2017-06-13 Dnmt1の阻害剤としての置換ピリジン Active JP7051829B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662349227P 2016-06-13 2016-06-13
US62/349,227 2016-06-13
US201662393256P 2016-09-12 2016-09-12
US62/393,256 2016-09-12
US201662412343P 2016-10-25 2016-10-25
US62/412,343 2016-10-25
PCT/IB2017/053511 WO2017216727A1 (en) 2016-06-13 2017-06-13 Substituted pyridines as inhibitors of dnmt1

Publications (3)

Publication Number Publication Date
JP2019517596A JP2019517596A (ja) 2019-06-24
JP2019517596A5 true JP2019517596A5 (enExample) 2020-07-27
JP7051829B2 JP7051829B2 (ja) 2022-04-11

Family

ID=59239935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019517187A Active JP7051829B2 (ja) 2016-06-13 2017-06-13 Dnmt1の阻害剤としての置換ピリジン

Country Status (20)

Country Link
US (1) US10975056B2 (enExample)
EP (1) EP3468953B1 (enExample)
JP (1) JP7051829B2 (enExample)
KR (1) KR20190017030A (enExample)
CN (1) CN109563043B (enExample)
AU (1) AU2017283790B2 (enExample)
CA (2) CA3026226A1 (enExample)
CL (1) CL2018003577A1 (enExample)
CO (1) CO2018013717A2 (enExample)
CR (1) CR20180580A (enExample)
DO (1) DOP2018000273A (enExample)
ES (1) ES2993451T3 (enExample)
IL (1) IL263163B (enExample)
JO (1) JOP20180120A1 (enExample)
MA (1) MA45244A (enExample)
MX (1) MX391600B (enExample)
PE (1) PE20190971A1 (enExample)
PH (1) PH12018502633B1 (enExample)
SG (1) SG11201809559UA (enExample)
WO (2) WO2017216727A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
JP6636673B2 (ja) 2016-10-04 2020-01-29 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. STINGアゴニストとしてのベンゾ[b]チオフェン化合物
ES2982801T3 (es) 2017-03-28 2024-10-17 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
AU2018311965A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
WO2019072143A1 (zh) * 2017-10-11 2019-04-18 上海迪诺医药科技有限公司 4-氨基吡啶衍生物、其药物组合物、制备方法及应用
WO2019125974A1 (en) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
US10793557B2 (en) 2018-04-03 2020-10-06 Merck Sharp & Dohme Corp. Sting agonist compounds
KR102692309B1 (ko) 2019-01-15 2024-08-07 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
WO2020172075A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
CN111662283B (zh) * 2019-03-07 2021-11-16 湖南化工研究院有限公司 咪唑并吡啶类化合物及其中间体、制备方法与应用
WO2022076563A1 (en) * 2020-10-07 2022-04-14 University Of Florida Research Foundation, Incorporated Macrocyclic compounds and methods of treatment
CA3212345A1 (en) * 2021-03-02 2022-09-09 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as dnmt1 inhibitors
CN113502265B (zh) * 2021-05-25 2024-05-28 昭泰英基生物医药(香港)有限公司 将t细胞重编程为类nk细胞的诱导剂及其应用
CN113278021B (zh) * 2021-05-29 2022-09-23 天津全和诚科技有限责任公司 1,7-二氮杂螺[3.5]壬烷-7-甲酸叔丁酯及其草酸盐的制备方法
MX2024004801A (es) 2021-10-19 2024-06-28 Akirabio Inc Composiciones que comprenden análogos de 2'- desoxicitidina, y uso de las mismas para el tratamiento de anemia de células falciformes, talasemia y cánceres.
CN114230459A (zh) * 2021-12-10 2022-03-25 武汉九州钰民医药科技有限公司 一种化合物的制备方法及分析检测方法
WO2023192629A1 (en) * 2022-04-01 2023-10-05 Herophilus, Inc. Induction of mecp2 expression by dna methyl transferase inhibitors
WO2024156288A1 (en) * 2023-01-29 2024-08-02 Shanghai Kygent Pharmaceutical Co., Ltd Dnmt1 inhibitors, pharmaceutical compositions, and therapeutic applications
WO2025006902A2 (en) * 2023-06-29 2025-01-02 Dana-Farber Cancer Institute, Inc. Synthesis and in vitro characterization of proteolysis targeting chimeras (protacs) for degradation of dna methyltransferase 1 (dnmt1)
WO2025085756A1 (en) * 2023-10-18 2025-04-24 University Of Florida Research Foundation, Incorporated Macrocyclic compounds and methods of treatment
WO2025190286A1 (en) * 2024-03-12 2025-09-18 Shanghai Kygent Pharmaceutical Co., Ltd Pyridine compounds, pharmaceutical compositions, and applications
CN119306700B (zh) * 2024-08-28 2026-06-02 山东大学 Dnmt1-hdac双靶点抑制剂及其制备方法和应用
WO2026164985A1 (en) 2025-01-28 2026-08-06 Icahn School Of Medicine At Mount Sinai Dna methyltransferase 1 (dnmt1) monovalent degraders

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030875C (en) 1990-11-26 2002-07-02 Alan R.P. Paterson Methods and probes for detecting nucleoside transporter and method for producing the probes
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
WO1994022853A1 (en) 1993-03-26 1994-10-13 Shell Internationale Research Maatschappij B.V. Herbicidal 1-heteroaryl pyrazolidin-3,5-diones
TR199801255T2 (xx) 1995-12-29 1998-10-21 Smithkline Beecham Corporation Vitronektin resept�r antagonistleri.
WO1997024124A1 (en) 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
DE19947154A1 (de) * 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
WO2001044172A1 (en) 1999-12-15 2001-06-21 Axys Pharmaceuticals, Inc. Salicylamides as serine protease and factor xa inhibitors
US6794506B2 (en) 2000-07-21 2004-09-21 Elan Pharmaceuticals, Inc. 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
US20030166554A1 (en) 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
DE10110754A1 (de) * 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10134481A1 (de) * 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
TW200406370A (en) 2002-06-28 2004-05-01 Syngenta Participations Ag 4-(3,3-Dihalo-allyloxy)phenoxy alkyl derivatives
AR043048A1 (es) 2002-08-30 2005-07-13 Syngenta Participations Ag Derivados de 4-(3,3-dihalo- aliloxi) fenol con propiedades pesticidas
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
AR042344A1 (es) 2002-12-11 2005-06-15 Syngenta Participations Ag Derivados de 4-(3,3 - dihalo - aliloxi) fenol con propiedades pesticidas
SE0203712D0 (sv) 2002-12-13 2002-12-13 Astrazeneca Ab Novel compounds
JP4895806B2 (ja) 2003-04-09 2012-03-14 エクセリクシス, インク. Tie−2モジュレータと使用方法
ATE556067T1 (de) 2003-05-20 2012-05-15 Ajinomoto Kk Modulatoren des vanilloid rezeptors
CN1856307A (zh) 2003-09-23 2006-11-01 默克公司 喹啉钾通道抑制剂
AU2011253934C1 (en) 2004-06-17 2013-08-22 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
EP1655296A1 (en) 2004-10-25 2006-05-10 Graffinity Pharmaceuticals AG Thrombin inhibitors
EP1844062A2 (en) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibitors of dna methyltransferase
GB0517740D0 (en) 2005-08-31 2005-10-12 Novartis Ag Organic compounds
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
WO2007148738A1 (ja) 2006-06-20 2007-12-27 Ishihara Sangyo Kaisha, Ltd. 新規なピリジル-メタナミン誘導体又はその塩を含有する有害生物防除剤
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
JP2010517989A (ja) 2007-02-01 2010-05-27 アストラゼネカ アクチボラグ Hsp90阻害剤としての5,6,7,8−テトラヒドロプテリジン誘導体
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
WO2009034433A2 (en) 2007-09-10 2009-03-19 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
ES2446932T3 (es) 2007-10-08 2014-03-10 Advinus Therapeutics Private Limited Derivados de acetamida como activadores de glucoquinasa, su procedimiento y aplicaciones en medicina
US8343966B2 (en) 2008-01-11 2013-01-01 Novartis Ag Organic compounds
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
TW201028381A (en) * 2008-07-14 2010-08-01 Shionogi & Co Pyridine derivative having ttk inhibition activity
TW201011017A (en) 2008-08-19 2010-03-16 Astrazeneca Ab Chemical compounds 495-1
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
KR101146010B1 (ko) * 2009-09-10 2012-05-16 서울대학교산학협력단 TNF-α 매개성 질환의 예방 및 치료용 조성물
CN102686584A (zh) 2009-11-13 2012-09-19 盐野义制药株式会社 具有氨基连接基的氨基噻嗪或氨基噁嗪衍生物
WO2011079274A1 (en) 2009-12-23 2011-06-30 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
EP2516434B1 (en) 2009-12-23 2015-05-27 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones as syk inhibitors
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
US9073903B2 (en) 2010-02-17 2015-07-07 Jasco Pharmaceuticals, LLC Imidazole-2,4-dione inhibitors of casein kinase 1
WO2011150156A2 (en) 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US9422262B2 (en) 2010-09-24 2016-08-23 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
WO2012099807A1 (en) 2011-01-17 2012-07-26 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
WO2012170931A2 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20140256740A1 (en) 2011-07-29 2014-09-11 Tempero Pharmaceuticals, Inc. Compounds and methods
EP2736329A4 (en) 2011-07-29 2015-03-25 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
US20140357594A1 (en) * 2011-10-24 2014-12-04 Glaxosmithkline Intellectual Property (No.2) Limited New compounds
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
JP6535430B2 (ja) 2012-09-28 2019-06-26 イグニタ、インク. 非定型プロテインキナーゼcのアザキナゾリン阻害薬
CN106211771A (zh) 2014-01-21 2016-12-07 沃克哈特有限公司 含氮化合物及其作为抗菌剂的用途
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP7216682B2 (ja) Usp30阻害剤としての1-シアノ-ピロリジン化合物
US12071428B2 (en) Indazole compounds as kinase inhibitors
ES2727376T3 (es) Derivados de aminotriazina útiles como compuestos inhibidores de quinasa de unión TANK
ES2523892T3 (es) Derivados triazol y utilización de los mismos para trastornos neurológicos
JP2022531801A5 (enExample)
CN102112467B (zh) 作为激酶抑制剂的嘧啶衍生物
AU2010286569B2 (en) Compounds and compositions as protein kinase inhibitors
JP2022531801A (ja) フェニルアミノピリミジンアミドオートファジー阻害剤およびその使用方法
HRP20240293T1 (hr) Derivati kinazolina kao protutumorska sredstva
JP2010512338A5 (enExample)
JP2025540958A (ja) 蕁麻疹の治療のための野生型c-kitキナーゼ阻害剤としてのN-フェニル-ピラゾロ[1,5-A]ピリジン-3-カルボキサミド誘導体
CN108430993A (zh) Tank-结合激酶抑制剂化合物
US11352340B2 (en) Pyridine and pyridimine compounds as PI3K-gamma inhibitors
JP7736669B2 (ja) [1,2,4]トリアゾロ[1,5-c]キナゾリン-5-アミン
JP2017530999A5 (enExample)
RU2009125897A (ru) Ингибиторы фосфоинозитид-3-киназы и способы их применения
JP7250011B2 (ja) P2x3阻害剤としての新規なピラゾロ-ピロロ-ピリミジン-ジオン誘導体
JP2019508384A (ja) 5−置換2−(モルホリン−4−イル)−1,7−ナフチリジン
AU2016270373A1 (en) Triazoles for the treatment of demyelinating diseases
JP7651590B2 (ja) アミノピリミジン誘導体およびアリール炭化水素受容体モジュレーターとしてのその使用
US20250368666A1 (en) Indazole compounds
WO2017157792A1 (en) Combinations of copanlisib
JP2022539208A (ja) チロシンキナーゼ非受容体1(tnk1)阻害剤およびその使用
WO2020203610A1 (ja) 関節リウマチを治療するためのt型カルシウムチャネル阻害剤の使用
JP2024511841A (ja) 置換された1-アリール-1’-ヘテロアリール化合物、置換された1,1’-ビヘテロアリール化合物、及びこれらを使用する方法